Treatment of inflammatory muscle disease in adults

Joint Bone Spine

Volumn 77, Issue 5, 2010, Pages 390-394

  Tournadre, Anne ^a   Dubost, Jean Jacques ^a   Soubrier, Martin ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Dermatomyositis; Inclusion body myositis; Inflammatory muscle disease; Polymyositis

Indexed keywords

AZATHIOPRINE; CREATINE KINASE; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AUTOIMMUNE DISEASE; BOLUS INJECTION; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DRUG COST; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; INFLAMMATORY MUSCLE DISEASE; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; MUSCLE FUNCTION; MUSCLE STRENGTH; MYOSITIS; PLASMAPHERESIS; POLYMYOSITIS; REMISSION; RHEUMATOID ARTHRITIS; SHORT SURVEY; SKELETAL MUSCLE; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DISEASE PROGRESSION; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MYCOPHENOLIC ACID; MYOSITIS; RECEPTORS, INTERLEUKIN-1; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957877047     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.04.007     Document Type: Short Survey

References (74)

1. Bohan A., Peter J.B. Polymyositis and dermatomyositis. N Engl J Med 1975, 292:344-347.
2. Benveniste O., Dubourg O., Herson S. La myosite à inclusions. Rev Rhum 2008, 75:151-156.
3. Hoogendijk J.E., Amato A.A., Lecky B.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004, 14:337-345.
4. Troyanov Y., Targoff I.N., Tremblay J.L., et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005, 84:231-249.
5. Imbert-Masseau A., Hamidou M., Agard C., et al. Antisynthetase syndrome. Joint Bone Spine 2003, 70:161-168.
6. Sordet C., Goetz J., Sibilia J. Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease. Joint Bone Spine 2006, 73:646-654.
7. Sultan S.M., Ioannou Y., Moss K., et al. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology 2002, 41:22-26.
8. Laxer R.M., Stein L.D., Petty R.E. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum 1987, 30:328-334.
9. Seshadri R., Feldman B.M., Ilowite N., et al. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum 2008, 59:989-995.
10. Matsubara S., Sawa Y., Takamori M., et al. Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 1994, 57:1008.
11. Iorizzo L.J., Jorizzo J.L. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol 2008, 59:99-112.
12. Philipps B.A., Zilko P., Garlepp M.J., et al. Frequency of relapses in patients with polymyositis and dermatomyositis. Muscle Nerve 1998, 1668-1672.
13. Bronner I.M., van der Meulen M.F., de Visser M., et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006, 65:1456-1461.
14. Bunch T.W., Worthington J.W., Combs J.J., et al. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 1980, 92(3):365-369.
15. Ramanan A.V., Campbell-Webster N., Ota S., et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005, 52:3570-3578.
16. Badrising U.A., Maat-Schieman M.L., Ferrari M.D., et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002, 51:369-372.
17. Vencovský J., Jarosová K., Machácek S., et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000, 29:95-102.
18. Miller J., Walsh Y., Saminaden S., et al. Randomized double blind trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 2002, 199(Suppl.):S53.
19. Villalba L., Hicks J.E., Adams E.M., et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998, 41:392-399.
20. Gelber A.C., Nousari H.C., Wigley F.M. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 2000, 27:1542-1545.
21. Hervier B., Masseau A., Mussini J.M. Long-term efficacy of mycophenolate mofetil in a case of refractory antisynthetase syndrome. Joint Bone Spine 2009, 76:575-576.
22. Schneider C., Gold R., Schäfers M., et al. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002, 25:286-288.
23. Majithia V., Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005, 44:386-389.
24. Rowin J., Amato A.A., Deisher N., et al. Mycophenolate mofetil in dermatomyositis: is it safe?. Neurology 2006, 66:1245-1247.
25. Edge J.C., Outland J.D., Dempsey J.R., et al. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006, 142:65-69.
26. Pisoni C.N., Cuadrado M.J., Khamashta M.A., et al. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 2007, 46:516-518.
27. Caramaschi P., Volpe A., Carletto A., et al. Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature. Clin Rheumatol 2007, 26:1795-1796.
28. Saketkoo L.A., Espinoza L.R. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009, 337:329-335.
29. Lange U., Piegsa M., Müller-Ladner U., et al. Anti-Jo-1 antibody positive polymyositis--successful therapy with leflunomide. Autoimmunity 2006, 39:261-264.
30. Boswell J.S., Costner M.I. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol 2008, 58:403-406.
31. Sangle V.S., Sangle S.R., D'Cruz D.P. Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis. Ann Rheum Dis 2008, 67:723.
32. Kameda H., Nagasawa H., Ogawa H., et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005, 32:1719-1726.
33. Yamasaki Y., Yamada H., Yamasaki M., et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007, 46:124-130.
34. Dalakas M.C., Illa I., Dambrosia J.M., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993-2000.
35. Cherin P., Pelletier S., Teixeira A., et al. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002, 46:467-474.
36. Danieli M.G., Calcabrini L., Calabrese V., et al. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev 2009, 9:124-127.
37. Marie I., Hachulla E., Levesque H., et al. Intravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositis. J Rheumatol 1999, 26:2706-2709.
38. Tournadre A., Porcherot M., Chérin P., et al. Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine 2009, 46:297-301.
39. Dalakas M.C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004, 291:2367-2375.
40. Chevrel G., Granet C., Miossec P. Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis 2005, 64:1257-1262.
41. Efthimiou P., Schwartzman S., Kagen L.J. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006, 65:1233-1236.
42. Riley P., McCann L.J., Maillard S.M., et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008, 47:877-880.
43. Iannone F., Scioscia C., Falappone P.C., et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006, 33:1802-1804.
44. Hengstman G.J., De Bleecker J.L., Feist E., et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008, 59:159-163.
45. Dastmalchi M., Grundtman C., Alexanderson H., et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008, 67:1670-1677.
46. Barohn R.J., Herbelin L., Kissel J.T., et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 2006, 66(Suppl. 1):S123-124.
47. Eloranta M.L., Barbasso Helmers S., Ulfgren A.K., et al. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007, 56:3112-3124.
48. Furlan A., Botsios C., Ruffatti A., et al. Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint Bone Spine 2008, 75:366-367.
49. Levine T.D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005, 52:601-607.
50. Lambotte O., Kotb R., Maigne G., et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005, 32:1369-1370.
51. Chiappetta N., Steier J., Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 2005, 11:264-266.
52. Noss E.H., Hausner-Sypek D.L., Weinblatt M.E. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006, 33:1021-1026.
53. Arlet J.B., Dimitri D., Pagnoux C., et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006, 16:334-336.
54. Brulhart L., Waldburger J.M., Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006, 65:974-975.
55. Dinh H.V., McCormack C., Hall S., et al. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007, 56:148-153.
56. Chung L., Genovese M.C., Fiorentino D.F. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007, 143:763-767.
57. Mok C.C., Ho L.Y., To C.H. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007, 34:1864-1868.
58. Touma Z., Arayssi T., Kibbi L., et al. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine 2008, 75:334-337.
59. Tournadre A., Amarger S., Joly P., et al. Polymyositis and pemphigus vulgaris in a patient: successful treatment with rituximab. Joint Bone Spine 2008, 75:728-729.
60. Feist E., Dörner T., Sörensen H., et al. Longlasting remissions after treatment with rituximab for autoimmune myositis. J Rheumatol 2008, 35:1230-1232.
61. Sultan S.M., Ng K.P., Edwards J.C., et al. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 2008, 26:887-893.
62. Miller F.W., Leitman S.F., Cronin M.E., et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992, 326:1380-1384.
63. Fathi M., Vikgren J., Boijsen M., et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008, 59:677-685.
64. Ochi S., Nanki T., Takada K., et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol 2005, 23:707-710.
65. Guglielmi S., Merz T.M., Gugger M., et al. Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus. Eur Respir J 2008, 31:213-217.
66. Kotani T., Makino S., Takeuchi T., et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 2008, 35:254-259.
67. Horber F.F., Scheidegger J.R., Grunig B.E., et al. Evidence that prednisone-induced myopathy is reversed by physical training. J Clin Endocrinol Metab 1985, 61:83-88.
68. Wiendl H. Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics 2008, 5:548-557.
69. Alexanderson H., Dastmalchi M., Esbjornsson-Liljedahl M., et al. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum 2007, 57:768-777.
70. de Salles Painelli V., Gualano B., Artioli G.G., et al. The possible role of physical exercise on the treatment of idiopathic inflammatory myopathies. Autoimmun Rev 2009, 8:355-359.
71. Nguyen K., Bassez G., Krahn M., et al. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 2007, 64:1176-1182.
72. Tournadre A., Soubrier M. Le rhumatologue face à une myopathie cortisonique. Rev Rhum 2008, 75:157-161.
73. Oh T.H., Brumfield K.A., Hoskin T.L., et al. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc 2007, 82:441-447.
74. Dalakas M.C., Rakocevic G., Schmidt J., et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009, 132:1536-1544.